NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Shanghai Pulmonary Hospital, Shanghai, China100 enrolled

Overview

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Non-small Cell Lung Cancer

Interventions

TimeOTHER

Different detecting time

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy Exclusion Criteria: EGFR mutant positive Alk mutant positive

Locations (1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

numbers of immune cells

detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Time frame: 24 months

Secondary Outcomes

numbers of tumor mutations

detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.